Lipophilic isosteres of a π-π Stacking interaction: New inhibitors of the Bcl-2-Bak protein-protein interaction

ACS Medicinal Chemistry Letters

Volumn 3, Issue 7, 2012, Pages 579-583

  Yusuff, Naeem ^a   Doré, Michaël ^a   Joud, Carol ^a   Visser, Michael ^a   Springer, Clayton ^a   Xie, Xiaoling ^a   Herlihy, Kara ^a   Porter, Dale ^a   Touré, B Barry ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

stacking interactions; stacking isosteres; Bcl 2 inhibitors; bioisoteres; cancer therapeutics; protein.protein interaction

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; PROTEIN BAK; PROTEIN BCL 2;

ARTICLE; CIRCLING BEHAVIOR; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; X RAY CRYSTALLOGRAPHY;

RATTUS;

EID: 84863845342     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300095a     Document Type: Article

References (22)

1. Keskin, O.; Gursoy, A.; Ma, B.; Nussinov, R. Principles of Protein-Protein Interactions: What are the Preferred Ways For Proteins To Interact? Chem. Rev. 2008, 108, 1225-1244
2. L from NMR and Parallel Synthesis J. Med. Chem. 2006, 49, 656-663
3. Wendt, W. D. Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction Expert Opin. Drug Discovery 2008, 3, 1123-1143
4. Park, C.-M.; Bruncko, M.; Adickes, J.; Bauch, J.; Ding, H.; Kunzer, A.; Kennan, M. C.; Nimmer, P.; Shoemaker, A. R.; Song, X.; Tahir, S. K.; Tse, C.; Wang, X.; Wendt, M. D.; Yang, X.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H.; Elmore, S. Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins J. Med. Chem. 2008, 51, 6902-6915
5. Oltersdorf, T.; Elmore, S. W.; Shoemaker, A. R.; Armstrong, R. C.; Augeri, S. W.; Belli, B. A.; Bruncko, M.; Deckwerth, T. L.; Dinges, J.; Hajduk, P. J.; Joseph, M. K.; Kitada, S.; Korsmeyer, S. J.; Kunzer, A. R.; Letai, A.; Li, C.; Mitten, M. J.; Nettesheim, D. J.; Ng, S.; Nimmer, P. M.; O'Connor, J. M.; Oleksijew, A.; Petros, A. M.; Reed, J. C.; Shen, W.; Tahir, S. K.; Thompson, C. B.; Tomaselli, K. J.; Wang, B.; Wendt, M. D.; Zhang, H.; Fesik, S. W.; Rosenberg, S. H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours Nature 2005, 435, 677-681
6. Tse, C.; Shoemaker, A. R.; Adickes, J.; Anderson, M. G.; Chen, J.; Jin, S.; Johnson, E. F.; Marsh, K. C.; Mitten, M. J.; Nimmer, P.; Roberts, L.; Tahir, S. K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S. H.; Elmore, S. W. ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor Cancer Res. 2008, 68, 3421-3428
7. Cory, S.; Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch Nat. Rev. Cancer 2002, 2, 647-656
8. Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer Cell 2000, 100, 57-70
9. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points Cell 2004, 116, 205-219
10. Berghella, A. M.; Pellegrini, P.; Contasta, I.; Del Beato, T.; Adorno, D. Bcl-2 and Drugs Used in the Treatment of Cancer: New Strategies of Biotherapy which should not be Underestimated Cancer Biother. Radiopharm. 1998, 13, 225-236
11. Reed, J. C. Mechanisms of apoptosis avoidance in cancer Curr. Opin. Oncol. 1999, 11, 68-75
12. Kusenda, J. Bcl-2 family proteins and leukemia Neoplasma (Bratisl.) 1998, 45, 117-122
13. Lee, E. F.; Czabotar, P. E.; Smith, B. J.; Deshayes, K.; Zobel, K.; Colman, P. M.; Fairlie, W. D. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family Cell Death Differ. 2007, 14, 1711-1713
14. Sattler., M.; Liang, H.; Nettesheim, D.; Meadows, R. P.; Harlan, J. E.; Eberstadt, M.; Yoon, H. S.; Shuker, S. B.; Chang, B. S.; Minn, A. J.; Thompson, C. B.; Fesik, S. W. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis Science 1997, 275, 983-986
15. Lipinsky, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
16. Koshland, D. The active site and enzyme action Adv. Enzymol. Relat. Subj. Biochem. 1960, 22, 45-97
17. Bartlett, P. A.; Yusuff, N.; Pyun, H.-J.; Rico, A. C.; Meyer, J. H.; Smith, W. W.; Burger, M. T. Design of Macrocyclic Peptidase Inhibitors: The Related Roles of Structure based Approaches and Library Chemistry. In Medicinal Chemistry into the Millenium Spec. Publ.-R. Soc. Chem. 2001, 264, 3-15
18. Hruby, V. J. Design in topographical space of peptide and peptidomimetic ligands that affect behavior. A chemist's glimpse at the mind-body problem Acc. Chem. Res. 2001, 34, 389-397
19. L J. Am. Chem. Soc. 2006, 128, 16206-16212
20. Goreshnik, I.; Brock, A. M.; Maly, D. J. Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL Bioorg. Med. Chem. Lett. 2011, 21, 4951-4955
21. Toshikazu, K.; Yuichi, I.; Matsubara, H.; Hobara, D.; Kakiuchi, T.; Okazaki, T.; Komatsu, K. Rigid Molecular Tripod with an Adamantane Framework and Thiol Legs. Synthesis and Observation of an Ordered Monolayer on Au(111) J. Org. Chem. 2006, 71, 1362-1369
22. Thea, S.; Cevasco, G. A facile synthesis of sulfinyl chlorides from thiolacetates Tetrahedron Lett. 1987, 28, 5193-5194